← Leaderboards
Moataz Reda
Pdx Pharmaceuticals, Inc.
$570,260
Attributed
$1,710,781
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2021–23$2M$1.5M$1M$500K$0
'21
'22
'23
Funding mix
By agency
NIH$1,710,781 · 2
By mechanism
R44$1,710,781 · 2
Top collaborators
- Worapol Ngamcherdtrakul3 shared
- Wassana Yantasee3 shared
Most similar at Pdx Pharmaceuticals, Inc.
Same institution · by research overlap
- Worapol Ngamcherdtrakul$4,005,298
Others in their field
Other Emerging Leaders on “Hematology”
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Olwen Hahn · Brigham And Women'S Hospital$32,185,622
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Patricia Shifflett · Westat, Inc.$16,650,520
- Bronwen Shaw · Medical College Of Wisconsin$15,731,163
- Ashok Kumar Krishnamurthy · Univ Of North Carolina Chapel Hill$14,385,480
Research focus
HematologyImmuneCessation Of LifeDrug KineticsCd8-Positive T-LymphocytesHumanized MouseCancer EtiologyCellsClinically RelevantDoseCancer PatientCancer TherapyHistologyBenchmarkingBilateralBody WeightBiodistributionCell DeathBiological MarkersCancer Cell LineCancer CellClinical TrialsAccountingImmunohistochemistry
Grant awards (3)
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$932,751
R44 · FY2023 · CA
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$400,000
R44 · FY2023 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$378,030
R44 · FY2021 · CA